Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

Tom Nolan reviews this week’s research An editorial about D-dimers likens the endlessly talked about blood test to a fine wine. It’s nothing to do with its taste (I find it a bit claggy) or cost, but ...

Our extensive research on the United States Anticoagulation Therapy (2024-2032) offers valuable insights for businesses. This comprehensive report delves into emerging trends, inv ...

Trials in AF and acute coronary syndrome were stopped early for futility, but there’s hope for factor XIa inhibitors given ...

Smartwatch-based monitoring using both photoplethysmography and ECG could improve detection of new-onset atrial fibrillation ...

The spectre of medical errors is a critically important subject, one that is as old as organised medical practice itself. What is striking, however, is not merely their longevity but their alarming ...

Dutch trial establishes feasibility of screening approach in routine specialty care ...

Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of ...

Penumbra has launched the Lightning Flash 3.0 thrombectomy system ahead of a $14.5B Boston Scientific acquisition.

This year, sales of Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity ...

Penumbra (NYSE:PEN) announced today that it launched the Lightning Flash 3.0 computer-assisted vacuum thrombectomy (CAVT) ...

The team's total artificial lung system, or TAL, bought the man precious time until a double lung transplant was viable.